

Vidarabine

[View the current Vidarabine InDepth page on BioPortfolio.com \(PDF\)](#)

(<http://www.bioportfolio.com/indepth/Vidarabine.html>) - Regularly Updated.

Vidarabine is an anti-viral drug which is active against herpes simplex and varicella zoster viruses. ([From the Wikipedia article Vidarabine.](#))



Recent Publications on Vidarabine:

- [5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.](#)
PURPOSE: A randomized trial of oblimersen plus... 18th November, 2009
Division of Hematology, The University of Texas M. D. Anderson Cancer- J Clin Oncol. 2009 Nov 1;27(31):5208-12. Epub 2009 Sep 8. ([DOI Direct Link](#))
- [Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis.](#)
T-cell prolymphocytic leukaemia (T-PLL) is a rare, aggressive neoplasm of... 13th November, 2009
Department of Dermatology, College of Medicine, Kyunghee University,- Acta Derm Venereol. 2009;89(5):509-12. ([DOI Direct Link](#))
- [First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.](#)
Although chronic lymphocytic leukemia (CLL) is a disease of elderly... 7th November, 2009
Department I of Internal Medicine, Centre of Integrated Oncology Koln- Blood. 2009 Oct 15;114(16):3382-91. Epub 2009 Jul 15. ([DOI Direct Link](#))
- [Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.](#)
PURPOSE: The addition of monoclonal antibodies to chemotherapy has... 5th November, 2009
Department of Hematology, Hospital Clinic, Villarroel 170, 08036- J Clin Oncol. 2009 Sep 20;27(27):4578-84. Epub 2009 Aug 24. ([DOI Direct Link](#))
- [Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.](#)
Nonrelapse mortality (NRM) after reduced-intensity allogeneic transplants... 3rd November, 2009
Department of Stem Cell Transplantation and Cellular Therapy, University- Biol Blood Marrow Transplant. 2009 Sep;15(9):1094-9. ([DOI Direct Link](#))
- [Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia \(CLL\): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.](#)
The prognosis of fludarabine (F)-refractory chronic lymphocytic leukemia... 29th October, 2009
Department of Internal Medicine III, University of Ulm, Ulm, Germany.- Blood. 2009 Sep 24;114(13):2589-97. Epub 2009 Jul 30. ([DOI Direct Link](#))

- [Inhibition of B virus \(Cercopithecine herpesvirus 1\) by Conventional and Experimental Antiviral Compounds.](#)
*B virus infection of humans results in high morbidity and mortality in up...*28th October, 2009
Viral Immunology Center, Georgia State University, and Laboratory of- Antimicrob Agents Chemother. 2009 Oct 26. ([DOI Direct Link](#))
- [Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts.](#)
*The resistance of malignant cells to chemotherapy calls for the...*17th October, 2009
Charles University in Prague, First Faculty of Medicine, Institute of- Proteomics. 2009 Oct 15;9(22):5006-5015. ([DOI Direct Link](#))
- [Pentostatin treatment combinations in chronic lymphocytic leukemia.](#)
*There have been great strides in the treatment of chronic lymphocytic...*29th September, 2009
Division of Hematology, Department of Medicine, Memorial Sloan-Kettering- Clin Adv Hematol Oncol. 2009 Jun;7(6):386-92.
- [Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.](#)
*BACKGROUND: Stem-cell transplantation can cure primary immunodeficiencies....*25th September, 2009
Great Ormond Street Children's Hospital, London, UK.- Lancet. 2009 Sep 12;374(9693):912-20. Epub 2009 Sep 2. ([DOI Direct Link](#))
- [Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.](#)
*B-cell chronic lymphocytic leukemia (CLL) is characterized by an...*24th September, 2009
Department of Cytochemistry, University of Lodz, Lodz, Poland.- Ann N Y Acad Sci. 2009 Aug;1171:124-31. ([DOI Direct Link](#))
- [Sequential adenovirus infection of type 14 hemorrhagic cystitis and type 35 generalized infection after cord blood transplantation.](#)
*We report a case of a 29-year-old male patient with a generalized...*19th September, 2009
Division of Hematology, Department of Regenerative and Transplant- Int J Hematol. 2009 Sep 11. ([DOI Direct Link](#))
- [Long-lasting response of chronic lymphocytic leukemia and multiple sclerosis in a patient treated with oral fludarabine alone.](#)
*PURPOSE: The addition of monoclonal antibodies to chemotherapy has...*11th September, 2009
- Tumori. 2009 May-Jun;95(3):406-7.
- [Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.](#)
*PURPOSE: The phase II CLL2H trial evaluated safety and efficacy of...*4th September, 2009
Department of Internal Medicine III, University of Ulm, Ulm, Germany.- J Clin Oncol. 2009 Aug 20;27(24):3994-4001. Epub 2009 Jul 13. ([DOI Direct Link](#))
- [Rituximab for polyneuropathy with IgM monoclonal gammopathy.](#)
*BACKGROUND: Polyneuropathy with IgM monoclonal gammopathy can be a...*3rd September, 2009
Department of Neurology and Rudolf Magnus Institute of Neurosciences,- J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):1036-9. ([DOI Direct Link](#))



Vidarabine Patents:

- 7550508- [Prostaglandin analog compositions and methods to treat epithelial-related conditions](#)
- 7566703- [Semi-soft C-class immunostimulatory oligonucleotides](#)
- 7569553- [Nucleic acid compositions for stimulating immune responses](#)
- 7569689- [Modulators of the glucocorticoid receptor, AP-1, and/or NF-.kappa.B activity and use thereof](#)
- 7572442- [Selected antibody compositions for binding to aminophospholipids](#)
- 7572448- [Combined cancer treatment methods using selected antibodies to aminophospholipids](#)
- 7572456- [Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof](#)
- 7576054- [Compositions and methods for treating bacteria](#)
- 7576066- [Nucleic acid compositions for stimulating immune responses](#)
- 7576068- [Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus](#)
- 7582297- [Methods of treating respiratory conditions](#)
- 7563899- [\(S\)-N-methylnaltrexone](#)
- 7563885- [Modulation of Tudor-SN expression](#)
- 7563884- [Antisense modulation of PTP1B expression](#)
- 7553816- [p-amidobenzylethers in drug delivery agents](#)
- 7553826- [Cytarabine monophosphate prodrugs](#)
- 7553874- [Prostaglandin analog compositions and methods to treat epithelial-related conditions](#)
- 7553875- [Prostaglandin analog compositions and methods to treat epithelial-related conditions](#)
- 7553944- [Human virus causing respiratory tract infection and uses thereof](#)
- 7557190- [Optimized proteins that target Ep-CAM](#)
- 7557251- [Production of gossypol co-crystals](#)
- 7560112- [Anti-il-6 antibodies, compositions, methods and uses](#)
- 7560263- [Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof](#)
- 7560544- [3,5-Disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo\[4,5-d\]pyrimidin-2-one compounds and prodrugs thereof](#)
- 7582438- [EphB receptor-binding peptides](#)
- 7582626- [5,6-dihydro-1H-pyridin-2-one compounds](#)
- 7598052- [Expression profile of thyroid cancer](#)
- 7598227- [Modulation of apolipoprotein C-III expression](#)
- 7601355- [Compositions and methods for altering immune function](#)
- 7601700- [Modulation of eIF4E expression](#)
- 7605135- [Baicalin as a treatment for SARS infection](#)
- 7605138- [Nucleic acid compositions for stimulating immune responses](#)
- 7605264- [Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-.kappa.B activity and use thereof](#)
- 7611704- [Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids](#)
- 7612033- [Methods for delivering compounds into a cell](#)
- 7615223- [Selected immunoconjugates for binding to aminophospholipids](#)
- 7595325- [Substituted pyrrolo\[2,3-d\]pyrimidine derivatives useful in cancer treatment](#)
- 7592461- [Indane modulators of glucocorticoid receptor, AP-1, and/or NF-.kappa.B activity and use thereof](#)

- 7592021- [Bioadhesive delivery system for transmucosal delivery of beneficial agents](#)
- 7582754- [Pyrro\[1,2-b\]pyridazinone compounds](#)
- 7582758- [Lewis acid mediated synthesis of cyclic esters](#)
- 7584059- [Inhibition of immune complex formation](#)
- 7585675- [Inhibition of HIV and SHIV replication with antisense interleukin-4](#)
- 7585851- [3'-prodrugs of 2'-deoxy-.beta.-L-nucleosides](#)
- 7588753- [Synergistically pro-penetrating solutions for unguual/peri-ungual dermatological/cosmetic applications](#)
- 7589079- [Crystalline and amorphous forms of beta-L-2'-deoxythymidine](#)
- 7589092- [Prodrugs of heteroaryl compounds](#)
- 7589233- [L-Threonine derivatives of high therapeutic index](#)
- 7592016- [Methods for preparing and using implantable substance delivery devices](#)
- 7615539- [Nucleic acid-lipophilic conjugates](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

